认知治疗药物CT1812显示,在用Lewy身体治疗痴呆症方面取得有希望的成果。 Cognition Therapeutics' drug CT1812 shows promising results in treating dementia with Lewy bodies.

认知治疗公司报告了CT1812对患有勒维体痴呆症的第二阶段"SHIMMER"研究的有希望的结果. Cognition Therapeutics has reported promising results from its Phase 2 'SHIMMER' study of CT1812 for dementia with Lewy bodies (DLB). 该药物在DLB病人的行为、认知和行动措施方面有显著改善,神经精神病症状减慢了82%,护理员的抑郁症也减少了。 The drug showed significant improvements in behavioral, cognitive, and movement measures in DLB patients, with an 82% slowing in neuropsychiatric symptoms and reduced caregiver distress. 完整的结果将在2025年1月的国际莱维体痴呆症会议上发表. The full results will be presented at the International Lewy Body Dementia Conference in January 2025.